CAPRICOR THERAPEUTICS, INC. — fact timeline

CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2026.

“today announced its financial results for the first quarter ended March 31, 2026”

CAPRICOR THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2025 results: revenue $0.

“Revenues for the fourth quarter of 2025 were $0”

Earl Collier resigned as Director at CAPRICOR THERAPEUTICS, INC..

“On April 8, 2025, Mr. Earl Collier, a member of the Board of Directors (the “Board”) of Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), informed the Board he will not stand for re-election to the Board following the Annual Meeting of Shareholders which is scheduled to occur on May 22, 2025.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Michael Kelliher as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Philip Gotwals, Ph.D. as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Paul Auwaerter, M.D. as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Karimah Es Sabar as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Earl M. Collier, Jr. as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of George W. Dunbar, Jr. as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of David B. Musket as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Linda Marbán, Ph.D. as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Frank Litvack, M.D. as director at the 2024-05-14 meeting.

“rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.”

CAPRICOR THERAPEUTICS, INC.: Increased authorized common stock from 50,000,000 to 100,000,000 shares (effective 2024-05-15).

“the stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 50,000,000 to 100,000,000. On May 15, 2024, the Company filed a Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect the Amendment, effective as of May 15, 2024.”

CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2024.

“On May 13, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.”

CAPRICOR THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.

“On February 29, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.”

CAPRICOR THERAPEUTICS, INC. reported financial results for the third quarter ended September 30, 2023.

“Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.”

CAPRICOR THERAPEUTICS, INC. entered into Purchase Agreement with certain institutional investors valued at approximately $23 million (effective 2023-09-29).

“On September 29, 2023, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Offering”), an aggregate of (a) 4,935,621 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), (the “Shares”) and (b) warrants to purchase 4,935,621 shares of the Company’s common stock (the “Warrants”) to the Purchasers.”

Michael Kelliher was elected as Director at CAPRICOR THERAPEUTICS, INC..

“On September 1, 2023, the Board of Directors (the “Board”) of Capricor Therapeutics, Inc. (the “Company”), pursuant to the authority given to it under the Certificate of Incorporation and Bylaws of the Company, approved an increase of the size of the Board from eight to nine directors, and thereafter elected Michael Kelliher as a member of the Board to fill the newly created vacancy, effective immediately.”

CAPRICOR THERAPEUTICS, INC. reported financial results for second quarter ended June 30, 2023.

“Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the second quarter ended June 30, 2023 and provided a corporate update.”

Philip Gotwals was elected as Director at CAPRICOR THERAPEUTICS, INC..

“approved an increase of the size of the Board from seven to eight directors, and elected Philip Gotwals, Ph.D. as a member of the Board to fill the newly created vacancy, effective immediately.”

Paul Auwaerter was elected as member of the Board of Directors at CAPRICOR THERAPEUTICS, INC..

“On July 11, 2023, the Board elected Paul Auwaerter, M.D. as a member of the Board, effective immediately.”

Louis Manzo resigned as member of the Board of Directors at CAPRICOR THERAPEUTICS, INC..

“On July 11, 2023, Mr. Louis Manzo, a member of the Board of Directors (the “Board”) of Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), resigned from the Board effective immediately.”

CAPRICOR THERAPEUTICS, INC.: Filed Certificate of Correction voiding the Certificate of Amendment, leaving Certificate of Incorporation unchanged (effective 2023-06-15).

“On June 15, the Company filed the Certificate of Correction with the Secretary of State of the State of Delaware voiding the Certificate of Amendment and causing the Certificate of Incorporation of the Company to remain unchanged from the Certificate of Incorporation of the Company as in effect prior to June 13, 2023.”

CAPRICOR THERAPEUTICS, INC. shareholders rejected Amendment to Certificate of Incorporation regarding officer exculpation at the 2023-06-12 meeting.

“4. The Company’s stockholders did not approve an amendment to the Certificate of Incorporation regarding officer exculpation. The votes were cast as follows: ​ ​ ​ ​ FOR AGAINST ABSTAIN BROKER NON-VOTES 5,037,656 1,816,404 103,335 9,390,464”

CAPRICOR THERAPEUTICS, INC. shareholders approved Advisory vote to approve named executive officer compensation at the 2023-06-12 meeting.

“3. The compensation of the Company’s named executive officers was approved, on a non-binding advisory basis, as follows: ​ ​ ​ ​ FOR AGAINST ABSTAIN BROKER NON-VOTES 4,328,964 2,446,891 181,541 9,390,463”

CAPRICOR THERAPEUTICS, INC. shareholders approved Ratification of appointment of Rose, Snyder & Jacobs LLP as independent registered public accounting firm at the 2023-06-12 meeting.

“2. The appointment by the Audit Committee of the Company’s Board of Directors of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified as follows: ​ ​ ​ ​ FOR AGAINST ABSTAIN BROKER NON-VOTES 14,556,113 448,170 1,343,576 0”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of seven nominees to the Board of Directors at the 2023-06-12 meeting.

“1. Each of Dr. Litvack, Dr. Marbán, Ms. Es Sabar, and Messrs. Musket, Dunbar, Manzo, and Collier were elected as directors of the Company to serve until the 2024 annual meeting of stockholders, and until his or her successor is elected, or until his or her earlier death, resignation or removal, as follows: ​ ​ ​ ​ ​ FOR WITHHELD BROKER NON-VOTES Frank Litvack, M.D. 5,848,468 1,108,927 9,390,464 Linda Marbán, Ph.D. 5,897,612 1,059,784 9,390,463 David B. Musket 4,907,731 2,049,664 9,390,464 George W. Dunbar, Jr. 5,838,850 1,118,545 9,390,464 Louis Manzo 5,887,307 1,070,088 9,390,464 Earl M. (Duke) Collier, Jr. 5,439,575 1,517,820 9,390,464 Karimah Es Sabar 5,899,808 1,057,588 9,390,463”

CAPRICOR THERAPEUTICS, INC.: Amended the Certificate of Incorporation to add exculpation of officers for monetary damages for breach of fiduciary duty, as permitted by Delaware law (effective 2023-06-13).

“On June 13, 2023, the Company filed a Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect the Amendment, effective as of June 13, 2023.”

CAPRICOR THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Certificate of Incorporation regarding officer exculpation at the 2023-06-12 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 5,037,656 1,816,404 103,335 9,390,464”

CAPRICOR THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on named executive officer compensation at the 2023-06-12 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 4,328,964 2,446,891 181,541 9,390,463”

CAPRICOR THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Rose, Snyder & Jacobs LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-12 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 14,556,113 448,170 1,343,576 0”

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of seven nominees to the Board of Directors to serve until the 2024 annual meeting at the 2023-06-12 meeting.

“FOR WITHHELD BROKER NON-VOTES Frank Litvack, M.D. 5,848,468 1,108,927 9,390,464 Linda Marbán, Ph.D. 5,897,612 1,059,784 9,390,463 David B. Musket 4,907,731 2,049,664 9,390,464 George W. Dunbar, Jr. 5,838,850 1,118,545 9,390,464 Louis Manzo 5,887,307 1,070,088 9,390,464 Earl M. (Duke) Collier, Jr. 5,439,575 1,517,820 9,390,464 Karimah Es Sabar 5,899,808 1,057,588 9,390,463”

CAPRICOR THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue approximately $3.0 million, net income approximately $7.8 million, or $0.31 per share, EPS $0.31 per share.

“U.S. Exclusive Commercialization and Distribution Agreement received from Nippon Shinyaku in the first quarter of 2022. Revenues for the first quarter of 2023 were approximately $3.0 million compared with zero for the first quarter of 2022. Operating expenses: Total operating expenses for the first quarter of 2023 were approximately $11.2 million compared with”

CAPRICOR THERAPEUTICS, INC. entered into Japan Agreement with Nippon Shinyaku, Co., Ltd. valued at upfront payment of $12 million and ... additional development and sales-based milestone payments of (effective 2023-02-10).

“Capricor Therapeutics, Inc. (the “Company” or “Capricor”) entered into an Exclusive Commercialization and Distribution Agreement (the “Japan Agreement”) with Nippon Shinyaku, Co., Ltd., a Japanese corporation, (“Nippon Shinyaku”) effective February 10, 2023.”

CAPRICOR THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue approximately $1.6 million, net income approximately $6.4 million, EPS $0.26 per share.

“For the three months ended September 30, 2022, the Company reported revenue of approximately $1.6 million compared with zero for the three months ended September 30, 2021. Operating expenses: Total operating expenses for the three months ended September 30, 2022, were approximately $8.1 million compared with approximately $4.3 million for the three months ended September 30, 2021. The Company reported a net loss of approximately $6.4 million, or $0.26 per share, for the third quarter of 2022, compared to a net loss of approximately $3.9 million, or $0.17 per share, for the third quarter of 2021.”